Published in Br J Pharmacol on September 01, 1991
Inhibition by phosphoramidon of the regional haemodynamic effects of proendothelin-2 and -3 in conscious rats. Br J Pharmacol (1992) 0.94
Investigation of the contributions of nitric oxide and prostaglandins to the actions of endothelins and sarafotoxin 6c in rat isolated perfused lungs. Br J Pharmacol (1996) 0.77
A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (1988) 27.60
The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A (1989) 7.41
Regional haemodynamic effects of endothelin-1 and endothelin-3 in conscious Long Evans and Brattleboro rats. Br J Pharmacol (1990) 1.80
Can pulsed Doppler technique measure changes in aortic blood flow in conscious rats? Am J Physiol (1990) 1.74
A novel peptide, vasoactive intestinal contractor, of a new (endothelin) peptide family. Molecular cloning, expression, and biological activity. J Biol Chem (1989) 1.49
Inhibition of biological actions of big endothelin-1 by phosphoramidon. Biochem Biophys Res Commun (1990) 1.39
Phosphoramidon blocks the pressor activity of porcine big endothelin-1-(1-39) in vivo and conversion of big endothelin-1-(1-39) to endothelin-1-(1-21) in vitro. Proc Natl Acad Sci U S A (1991) 1.26
Phosphoramidon, a metalloproteinase inhibitor, suppresses the hypertensive effect of big endothelin-1. Eur J Pharmacol (1990) 1.23
Putative precursors of endothelin have less vasoconstrictor activity in vitro but a potent pressor effect in vivo. FEBS Lett (1989) 1.20
Binding and receptor down-regulation of a novel vasoconstrictor endothelin in cultured rat vascular smooth muscle cells. FEBS Lett (1988) 1.18
NG-monomethyl-L-arginine does not inhibit the hindquarters vasodilator action of endothelin-1 in conscious rats. Eur J Pharmacol (1989) 1.16
Identification and characterization of endothelin converting activity in cultured bovine endothelial cells. Biochem Biophys Res Commun (1990) 1.08
Conversion of big endothelin-1 to endothelin-1 by two types of metalloproteinases derived from porcine aortic endothelial cells. FEBS Lett (1990) 1.03
Structure-activity relationship of endothelin: importance of charged groups. Biochem Biophys Res Commun (1989) 1.01
Conversion of porcine big endothelin to endothelin by an extract from the porcine aortic endothelial cells. Biochem Biophys Res Commun (1990) 1.00
Intravascular big endothelin increases circulating levels of endothelin-1 and prostanoids in the rabbit. Biochem Pharmacol (1990) 0.94
Hemodynamic and pharmacological evaluation of the vasodilator and vasoconstrictor effects of endothelin-1 in rats. J Pharmacol Exp Ther (1990) 0.93
Endothelin converting enzyme of bovine carotid artery smooth muscles. Biochem Biophys Res Commun (1991) 0.91
Vasodilation induced by endothelin: role of EDRF and prostanoids in rat hindquarters. Am J Physiol (1990) 0.91
No major role for atrial natriuretic peptide in the vasodilator response to endothelin-1 in the spontaneously hypertensive rat. Eur J Pharmacol (1990) 0.90
Evidence for pepstatin-sensitive conversion of porcine big endothelin-1 to endothelin-1 by the endothelial cell extract. Biochem Biophys Res Commun (1990) 0.90
Systemic and regional hemodynamic characterization of alpha-1 and alpha-2 adrenoceptor agonists in pithed rats. J Pharmacol Exp Ther (1987) 0.89
Regional distribution and pharmacological characterization of [125I]endothelin-1 binding sites in human fetal placental vessels. Placenta (1991) 0.84
Opposite effects of endothelin-1 and Big-endothelin-(1-39) on renal function in rats. Eur J Pharmacol (1990) 0.84
The potassium channel opener cromakalim (BRL 34915) activates ATP-dependent K+ channels in isolated cardiac myocytes. Biochem Biophys Res Commun (1988) 1.65
Role of the central autonomic nervous system in the hypotension and bradycardia induced by (-)-delta 9-trans-tetrahydrocannabinol. J Pharm Pharmacol (1974) 1.40
Differential effects of prazosin on the pre- and postsynaptic alpha-adrenoceptors in the rat and dog [proceedings]. Br J Pharmacol (1977) 1.15
Effects of prazosin and phentolamine on cardiac presynaptic alpha-adrenoceptors in the cat, dog and rat. Clin Exp Hypertens (1978) 1.15
Studies on the mechanism of the vasodilator effects of prazosin in dogs and rabbits. Eur J Pharmacol (1978) 1.13
Cardiovascular effects of prazosin in dogs. Clin Sci Mol Med Suppl (1976) 1.09
Potassium channel openers act through an activation of ATP-sensitive K+ channels in guinea-pig cardiac myocytes. Pflugers Arch (1989) 1.07
Preliminary studies on SL 75212, a new potent cardioselective beta-adrenoceptor antagonist [proceedings]. Br J Pharmacol (1979) 1.06
The pharmacology of prazosin, a novel antihypertensive agent. Life Sci (1980) 1.03
Cardiovascular characterization of DA-1 and DA-2 dopamine receptor agonists in anesthetized rats. Clin Exp Hypertens A (1987) 1.01
Urethane inhibits cardiovascular responses mediated by the stimulation of alpha-2 adrenoceptors in the rat. J Pharmacol Exp Ther (1982) 1.00
Pharmacological evidence for a role of ATP-dependent potassium channels in myocardial stunning. Circulation (1992) 0.99
The new K+ channel opener Aprikalim (RP 52891) reduces experimental infarct size in dogs in the absence of hemodynamic changes. J Pharmacol Exp Ther (1991) 0.98
Peripheral dopamine receptors, potential targets for a new class of antihypertensive agents. Part I: Subclassification and functional description. Life Sci (1982) 0.95
K+ channel openers and 'natural' cardioprotection. Trends Pharmacol Sci (1992) 0.95
"Calcium antagonists": a class of drugs with a bright future. Part II. Determination of basic pharmacological properties. Life Sci (1984) 0.95
Vasodilator activity of endothelin-1 and endothelin-3: rapid development of cross-tachyphylaxis and dependence on the rate of endothelin administration. J Pharmacol Exp Ther (1990) 0.93
Hemodynamic and pharmacological evaluation of the vasodilator and vasoconstrictor effects of endothelin-1 in rats. J Pharmacol Exp Ther (1990) 0.93
Cellular pharmacology of potassium channel openers in vascular smooth muscle. Cardiovasc Res (1994) 0.93
The effects of prazosin on the clonidine induced hypotension and bradycardia in rats and sedation in chicks [proceedings]. Br J Pharmacol (1978) 0.92
Time-course analysis of the cardiovascular effects of clonidine resulting from the activation of cardiac pre- and vascular postsynaptic alpha-adrenoceptors in the pithed rat [proceedings]. Br J Pharmacol (1978) 0.92
Nicorandil attenuates myocardial dysfunction associated with transient ischemia by opening ATP-dependent potassium channels. J Cardiovasc Pharmacol (1992) 0.91
Studies on the bradycardia induced by (-)- -trans-tetrahydrocannabinol in anesthetized dogs. Eur J Pharmacol (1973) 0.91
Comparative analysis of beta-1 adrenoceptor agonist and antagonist potency and selectivity of cicloprolol, xamoterol and pindolol. J Pharmacol Exp Ther (1987) 0.90
Systemic and regional hemodynamic characterization of alpha-1 and alpha-2 adrenoceptor agonists in pithed rats. J Pharmacol Exp Ther (1987) 0.89
"Calcium antagonists": a class of drugs with a bright future. Part I. Cellular calcium homeostasis and calcium as a coupling messenger. Life Sci (1983) 0.89
Effects of mianserin, desipramine and maprotiline on blood pressure responses evoked by acetylcholine, histamine and 5-hydroxytryptamine in rats. Br J Pharmacol (1981) 0.89
Studies on the rebound hypertension after clonidine withdrawal in conscious hypertensive cats, rats, and dogs [proceedings]. Br J Pharmacol (1977) 0.89
High affinity specific binding sites for tritiated platelet-activating factor in canine platelet membranes: counterparts of platelet-activating factor receptors mediating platelet aggregation. Mol Pharmacol (1988) 0.89
Frequency-independent blockade of cardiac Na+ channels by riluzole: comparison with established anticonvulsants and class I anti-arrhythmics. Fundam Clin Pharmacol (2000) 0.88
Nicorandil: differential contribution of K+ channel opening and guanylate cyclase stimulation to its vasorelaxant effects on various endothelin-1-contracted arterial preparations. Comparison to aprikalim (RP 52891) and nitroglycerin. J Pharmacol Exp Ther (1991) 0.88
Recent developments in noradrenergic neurotransmission and its relevance to the mechanism of action of certain antihypertensive agents. Hypertension (1980) 0.88
Rat juxtaglomerular cells are endowed with DA-1 dopamine receptors mediating renin release. J Cardiovasc Pharmacol (1988) 0.88
Diltiazem protects the isolated rabbit heart from the mechanical and ultrastructural damage produced by transient hypoxia, low-flow ischemia and exposure to Ca++-free medium. J Pharmacol Exp Ther (1983) 0.87
RP 55778, a PAF receptor antagonist, prevents and reverses LPS-induced hemoconcentration and TNF release. J Lipid Mediat (1992) 0.87
The contribution of guanylate cyclase stimulation and K+ channel opening to nicorandil-induced vasorelaxation depends on the conduit vessel and on the nature of the spasmogen. J Pharmacol Exp Ther (1994) 0.87
Hemodynamic and myocardial effects of (-)-delta9-trans-tetrahydrocannabinol in anesthetized dogs. Eur J Pharmacol (1973) 0.87
Endothelin--a new family of endothelium-derived peptides with widespread biological properties. Life Sci (1989) 0.87
Vascular beta-adrenoceptor stimulating properties of phenylephrine. Eur J Pharmacol (1977) 0.86
Cardiovascular and biological effects of K+ channel openers, a class of drugs with vasorelaxant and cardioprotective properties. Life Sci (1990) 0.86
Influence of depolarization on vasorelaxant potency and efficacy of Ca2+ entry blockers, K+ channel openers, nitrate derivatives, salbutamol and papaverine in rat aortic rings. Naunyn Schmiedebergs Arch Pharmacol (1998) 0.85
RP 58866 and its active enantiomer RP 62719 (terikalant): blockers of the inward rectifier K+ current acting as pure class III antiarrhythmic agents. J Cardiovasc Pharmacol (1992) 0.84
Functional and biochemical evidence for the lack of cardiac presynaptic alpha-2 adrenoceptor stimulant properties of cirazoline (LD 3098), a potent alpha-1 adrenoceptor agonist in dogs and rats. J Pharmacol Exp Ther (1982) 0.84
Regional distribution and pharmacological characterization of [125I]endothelin-1 binding sites in human fetal placental vessels. Placenta (1991) 0.84
Increase in plasma renin activity evoked by fenoldopam in dogs is directly mediated by dopamine1 receptor stimulation. J Cardiovasc Pharmacol (1989) 0.84
Inhibition of platelet adhesion to fibrin(ogen) in flowing whole blood by Arg-Gly-Asp and fibrinogen gamma-chain carboxy terminal peptides. Thromb Haemost (1992) 0.84
Effects of Ca2+ antagonists and K+-channel activators on K+-induced contractions in the rat aorta. J Auton Pharmacol (1989) 0.84
Differential inhibition of vascular smooth muscle responses to alpha 1- and alpha 2-adrenoceptor agonists by diltiazem and verapamil. Circ Res (1983) 0.84
Glibenclamide-induced blockade of ischemic preconditioning is time dependent in intact rat heart. Am J Physiol (1997) 0.83
Effects of clonidine, prazosin and phentolamine on heart rate and coronary sinus catecholamine concentration during cardioaccelerator nerve stimulation in spinal dogs. Br J Pharmacol (1979) 0.83
Effects of the K+ channel activators, RP 52891, cromakalim and diazoxide, on the plasma insulin level, plasma renin activity and blood pressure in rats. J Pharmacol Exp Ther (1991) 0.82
Certain observations on interrelationships between respiratory and cardiovascular effects of (-)- 9 -trans-tetrahydrocannabinol. Res Commun Chem Pathol Pharmacol (1972) 0.82
The blood pressure lowering effects of intravenous versus intracerebroventricular prazosin in anaesthetised cats. Eur J Pharmacol (1978) 0.82
SK&F 87516, a close analog of fenoldopam, is a partial agonist at dopamine-1 and alpha-2 receptors and produces stimulation of 5-hydroxytryptamine-2 receptors in the cardiovascular system of the rat. J Pharmacol Exp Ther (1991) 0.82
Activation of cardiac KATP channels: an endogenous protective mechanism during repetitive ischemia. Am J Physiol (1993) 0.82
Characterization of NK1 and NK2 tachykinin receptors in guinea-pig and rat bronchopulmonary and vascular systems. Br J Pharmacol (1994) 0.81
[3H]52770 RP, a platelet-activating factor receptor antagonist, and tritiated platelet-activating factor label a common specific binding site in human polymorphonuclear leukocytes. J Pharmacol Exp Ther (1988) 0.81
Contractile responses to calcium chloride in rat aortic rings bathed in K+-free solution are resistant to organic calcium antagonists. Br J Pharmacol (1989) 0.81
PAF binding sites. Characterization by [3H]52770 RP, a pyrrolo[1,2-c]thiazole derivative, in rabbit platelets. Biochem Pharmacol (1987) 0.81
Influence of pentobarbital anesthesia on the effects of certain autonomic blocking agents on heart rate. Eur J Pharmacol (1973) 0.81
Heart rate lowering effects of N,N-di-n-propyl-dopamine in rats: evidence for stimulation of central dopamine receptors leading to inhibition of sympathetic tone and enhancement of parasympathetic outflow. J Pharmacol Exp Ther (1981) 0.81
Comparison of mianserin with desipramine, maprotiline and phentolamine on cardiac presynaptic and vascular postsynaptic alpha-adrenoceptors and noradrenaline reuptake in pithed normotensive rats. Br J Pharmacol (1980) 0.81
Role of the sympathetic nervous system in blood pressure maintenance and in the antihypertensive effects of calcium antagonists in spontaneously hypertensive rats. Hypertension (1988) 0.81
Endothelin-1 binding sites and immunoreactivity in the cultured human placental trophoblast: evidence for an autocrine and paracrine role for endothelin-1. J Cardiovasc Pharmacol (1993) 0.80
Biochemical characterization and autoradiographic localization of [125I]endothelin-1 binding sites on trophoblast and blood vessels of human placenta. J Clin Endocrinol Metab (1993) 0.80
Comparison of cardiovascular actions of dihydralazine, phentolamine, and prazosin in spontaneously hypertensive rats. J Cardiovasc Pharmacol (1980) 0.80
Blood pressure lowering effects of N,N-di-n-propyl-dopamine in rats: evidence for stimulation of peripheral dopamine receptors leading to inhibition of sympathetic vascular tone. J Pharmacol Exp Ther (1981) 0.80
Effect of the platelet-activating factor antagonist RP 59227 (Tulopafant) on myocardial ischemia/reperfusion injury and neutrophil function. Basic Res Cardiol (1998) 0.80
Evidence for the existence and ionic modulation of platelet-activating factor receptors mediating degranulatory responses in human polymorphonuclear leukocytes. J Pharmacol Exp Ther (1989) 0.80
Sleeping times evoked by alpha adrenoceptor agonists in two-day-old chicks: an experimental model to evaluate full and partial agonists at central alpha-2 adrenoceptors. J Pharmacol Exp Ther (1983) 0.79
Studies on the mechanisms of the development of tolerance to the hypotensive effects of fenoldopam in rats. J Cardiovasc Pharmacol (1988) 0.79
Peripheral dopamine receptors, potential targets for a new class of antihypertensive agents. Part II: Sites and mechanisms of action of dopamine receptor agonists. Life Sci (1982) 0.79
Intervessel (arteries and veins) and heart/vessel selectivities of therapeutically used calcium entry blockers: variable, vessel-dependent indexes. J Pharmacol Exp Ther (1995) 0.79
Effects of clonidine on canine cardiac neuroeffector structures controlling heart rate. Br J Pharmacol (1980) 0.79
Time-dependent fading of the activation of KATP channels, induced by aprikalim and nucleotides, in excised membrane patches from cardiac myocytes. Br J Pharmacol (1995) 0.79
Functional validation of platelet-activating factor receptor sites characterized biochemically by a specific and reproducible [3H]platelet-activating factor binding in human platelets. J Pharmacol Exp Ther (1990) 0.79
Studies on the hypotensive activity of (-)-delta9-trans-tetrahydrocannabinol in anesthetized dogs. Res Commun Chem Pathol Pharmacol (1973) 0.79
Role of adrenocortical hormones on the ontogenesis of ventricular action potential of rat myocardium. J Mol Cell Cardiol (1981) 0.78
The effect of (minus)-delta 9-trans-tetrahydrocannibinol on myocardial contractility and venous return in anesthetized dogs. Eur J Pharmacol (1974) 0.78
Effects of mianserin on noradrenaline uptake, cardiac presynaptic and vascular postsynaptic alpha-adrenoceptors in rats [proceedings]. Br J Pharmacol (1979) 0.78
Mechanism of antihypertensive activity of orally administered prazosin in spontaneously hypertensive rats. J Cardiovasc Pharmacol (1980) 0.78
The platelet activating factor receptor antagonist, RP 59227, blocks platelet activating factor receptors mediating liberation of reactive oxygen species in guinea pig macrophages and human polymorphonuclear leukocytes. J Pharmacol Exp Ther (1991) 0.78
Pharmacological, hemodynamic and autonomic nervous system mechanisms responsible for the blood pressure and heart rate lowering effects of pergolide in rats. J Pharmacol Exp Ther (1984) 0.78
Cardiovascular characterization of the DA2 dopamine receptor agonist quinpirole in rats. Fundam Clin Pharmacol (1987) 0.77
Differential pharmacological profile of endothelin-1 and its precursor, big endothelin. J Cardiovasc Pharmacol (1991) 0.77
Effects of beta 2-adrenoceptor agonists on anti-IgE-induced contraction and smooth muscle reactivity in human airways. Br J Pharmacol (1995) 0.77
Stimulation of peripheral dopamine receptors in rats: a mechanism for novel antihypertensive agents. Clin Sci (Lond) (1980) 0.77
Effects of chronic guanethidine administration on cardiovascular function of dogs. Res Commun Chem Pathol Pharmacol (1975) 0.77
Evidence for NK-1 receptor subtypes from in vivo bronchopulmonary and cardiovascular studies. Regul Pept (1993) 0.77
Synthesis and antihypertensive activity of a series of 4-amino-6,7-dimethoxyquinazoline derivatives. J Med Chem (1986) 0.77
Parasympatholytic activity of (-)- 9 -trans-tetrahydrocannabinol in mongrel dogs. Eur J Pharmacol (1972) 0.76
Analysis of cardiac chronotropic responses to diazepam and bromazepam in conscious trained dogs. Eur J Pharmacol (1976) 0.76
Determination of constitution and synthesis of a new flavone from Cistus monspeliensis L. Tetrahedron (1967) 0.76
Effects of pergolide, a dopamine receptor agonist, and clonidine on cardiovascular responses evoked by activation of peripheral sympathetic outflow in rats. Clin Exp Hypertens A (1982) 0.76
Cardiovascular effects of diltiazem, a calcium antagonist, on isolated heart muscle preparations and in anaesthetized and pitched rats [proceedings]. Br J Pharmacol (1978) 0.75
Effects of diltiazem and verapamil on the mechanical performance of the rabbit myocardium perfused with an oxygenated and hypoxic medium [proceedings]. Br J Pharmacol (1979) 0.75
Influence of plasma protein content and platelet number on the potency of PAF and its antagonist RP 59227 in rabbit platelet preparations. Br J Pharmacol (1990) 0.75
Evidence against beta-adrenoceptor blocking activity of diltiazem, a drug with calcium antagonist properties. Br J Pharmacol (1980) 0.75
Enoxaparin (Clexane, Lovenox), a low molecular weight heparin, enhances t-PA-induced coronary thrombus lysis in anesthetized dogs without inducing hypocoagulability. Thromb Res (1992) 0.75
[Nicardipine: experimental antihypertensive action and interactions with the alpha-adrenergic sympathetic system]. J Pharmacol (1985) 0.75